ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1871

Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)

Zi Ying Li1, Siyi Huang2, Kevin Xi3, Deepan Dalal4 and Anthony Reginato5, 1Roger Williams Medical Center, Providence, RI, 2UCSF Fresno, Fresno, CA, 3Brown University, Providence, 4Brown University School of Medicine, Providence, RI, 5Brown University, Providence, RI

Meeting: ACR Convergence 2022

Keywords: Heart disease, Mortality, Myocardial Infarction, Myopathies, Outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample (NIS) study in 2021.1 The pathophysiology for cardiovascular damage in myositis is a multifactorial-process. Myositis can cause inflammation at the myocardium with accelerated coronary atherosclerosis.2 In addition, patients with IIM are at increased risk of heart failure, conduction abnormalities and venous thromboembolism .3,4,5 However, the presence of underlying inflammatory myositis and its direct impact on outcomes after acute myocardial infraction (AMI) and acute heart failure(AHF) has not been elucidated.

Methods: Using NIS database from 2016-19, which stratifies 20% of the total national hospital admissions, we identified patients with a primary admission diagnosis of AMI or AHF using ICD-10 codes. For each admission, we calculated the length of stay and ascertained the mortality. The independent variable for present or absence of myositis as a secondary diagnosis. Covariates of interest included baseline demographics and other comorbidities. The association of myositis with inpatient mortality and length of stay (LOS) was calculated using multivariable logistic regression.

Results: We identified 508,313 AMI hospitalization from 2016-2019, of which 512 patients had IMM. Patient in the myositis group were older in mean age (67 vs 69; p< 0.001), and had a higher proportion of females(37% vs 46%; p< 0.001). There was no difference in inpatient mortality between two groups of patients (4.6% vs 5.5%; p=0.3). In multivariable logistic regression model, after adjusting for age, race, gender, region, income and confounding comorbidities, there was continued to remain no significant difference in the odd of inpatient mortality between the two group (p=0.7). The LOS associated with myocardial infarction admission was longer in patient with IMM as compared to those without IMM . (Table. 1A/B)

We identified 220,647 AHF hospitalization from 2016-2019 with 303 patients had IMM. Myositis patients in this cohort were significantly younger (73 vs. 70; p< 0.001), and majority of them were female compared to the non-myositis group. (48% vs. 55%; p=0.007). There was no significant difference in hospitalization mortality for AHF between these two groups of patient (2.8% vs.3.6%; p=0.4). There was no significant difference in the odd of hospitalization mortality of AHF between these two groups. (p=0.5). The adjusted odds of LOS for acute heart failure in patients with IMM was significant longer compared to those without IMM (p< 0.001).(Table.2A/B)

Conclusion: Inpatient mortality in acute myocardial infraction and acute heart failure were similar in patient with and without IMM in this 4-year cohort study, whereas the LOS in both cohorts were longer in patients with myositis. The increase LOS may due to the extra time in work up or monitoring for myositis disease activity.

Supporting image 1

Hospitalization Mortality of Acute Myocardial Infraction in Patient Without and With Myositis in 2016_2019

Supporting image 2

Hospitalization Mortality of Acute Heart Failure in Patient Without and With Myositis in 2016_2019


Disclosures: Z. Li, None; S. Huang, None; K. Xi, None; D. Dalal, None; A. Reginato, None.

To cite this abstract in AMA style:

Li Z, Huang S, Xi K, Dalal D, Reginato A. Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/hospitalization-outcomes-for-acute-myocardial-infraction-and-acute-heart-failure-in-patients-with-idiopathic-inflammatory-myopathies-iim-from-2016-2019-national-inpatient-sample-nis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hospitalization-outcomes-for-acute-myocardial-infraction-and-acute-heart-failure-in-patients-with-idiopathic-inflammatory-myopathies-iim-from-2016-2019-national-inpatient-sample-nis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology